万达生物制药（Vanda Pharmaceuticals）近日呼吁美国食品药品监督管理局（FDA）从其2027财年立法议程中撤销一项旨在延长药物审评时间表的提案。该公司认为，此举可能对药物研发进程产生不利影响。
万达生物制药（Vanda Pharmaceuticals）近日呼吁美国食品药品监督管理局（FDA）从其2027财年立法议程中撤销一项旨在延长药物审评时间表的提案。该公司认为，此举可能对药物研发进程产生不利影响。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.